New therapy for rare metabolic disorder Pompe disease approved by US FDA

被引：0
|
作者：
不详
机构：
来源：
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2010年 / 5卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：479 / 479
页数：1
相关论文
共 50 条
  • [21] Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder
    Borland, Johnathan M.
    Kohut-Jackson, Abigail L.
    Peyla, Anna C.
    Hall, Megan A. L.
    Mermelstein, Paul G.
    Meisel, Robert L.
    NEUROPHARMACOLOGY, 2025, 267
  • [22] FDA Establishes Pilot Program to Accelerate Rare Disease Therapy Development
    Husni, Daria G.
    BIOPHARM INTERNATIONAL, 2023, 36 (12) : 14 - 14
  • [23] Acute Stroke Therapy With Tissue Plasminogen Activator (tPA) Since It Was Approved by the US Food and Drug Administration (FDA)
    Zivin, Justin A.
    ANNALS OF NEUROLOGY, 2009, 66 (01) : 6 - 10
  • [24] Gaucher's disease, prenatal diagnosis of a rare metabolic disorder
    Ritgen, J.
    Muetze, S.
    Piroth, D.
    Rath, W.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (04) : 403 - 403
  • [25] INFECTIOUS DISEASE First long-acting HIV therapy approved in US
    Satyanarayana, Megha
    CHEMICAL & ENGINEERING NEWS, 2021, 99 (04) : 11 - 11
  • [26] Confirmatory Evidence Used in Non-Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020-2023
    Nugent, Bridget M.
    Ramamoorthy, Anuradha
    Pippins, Jennifer R.
    Pepe, Salvatore
    Doi, Mary
    Thomas, Audrey
    Bagheri, Brandon
    Welsh, Cynthia
    Madabushi, Rajanikanth
    Lee, Kerry Jo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [27] New Therapeutic Approaches for Pompe Disease: Enzyme Replacement Therapy and Beyond
    Kishnani, Priya S.
    Beckemeyer, Alexandra A.
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 114 - 124
  • [28] Teaching tolerance New approaches to enzyme replacement therapy for Pompe disease
    Cousens, Leslie P.
    Mingozzi, Federico
    van der Marel, Sander
    Su, Yan
    Garman, Richard
    Ferreira, Valerie
    Martin, William
    Scott, David W.
    De Groot, Anne S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (10) : 1459 - 1464
  • [29] PATIENTS LEVEL COST OF TREATING ADVERSE EVENTS IN ALZHEIMER'S DISEASE FOR US-FDA APPROVED TREATMENTS
    Sanogo, V
    Almutairi, R.
    Diaby, K.
    VALUE IN HEALTH, 2023, 26 (12) : S179 - S180
  • [30] 2011 FDA drug approvals The US FDA approved 30 new therapeutics last year, including 11 first-in-class agents
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (02) : 91 - 94
12345